REFERENCES

Ali, Z., S. N. Raja, U. Wesselmann, P. N. Fuchs, R. A. Meyer, and J. N. Campbell. 2000. Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain. Pain 88(2):161-168.

Atanasoff, S., T. Ryan, R. Lightfoot, and R. Johann-Liang. 2010. Shoulder injury related to vaccine administration (sirva). Vaccine 28(51):8049-8052.

Bensasson, M., R. Lanoe, and R. Assan. 1977. A case of algodystrophic syndrome of the upper limb following tetanus vaccination [in French]. Semaine des Hopitaux 53(36):1965-1966.

Bernstein, D. I., F. Y. Aoki, S. K. Tyring, L. R. Stanberry, C. St.-Pierre, S. D. Shafran, G. Leroux-Roels, K. Van Herck, A. Bollaerts, and G. Dubin. 2005. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clinical Infectious Diseases 40(9):1271-1281.

Beytout, J., O. Launay, N. Guiso, A. Fiquet, M. Baudin, P. Richard, C. Baptiste, and B. Soubeyrand. 2009. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: A placebo-controlled trial. Human Vaccines 5(5):315-321.

Bino, S., E. Kakarriqi, M. Xibinaku, N. Ion-Nedelcu, M. Bukli, N. Emiroglu, and A. Uzicanin. 2003. Measles-rubella mass immunization campaign in Albania, November 2000. Journal of Infectious Diseases 187(Suppl. 1):S223-S229.

Black, S., H. Shinefield, J. Hansen, E. Lewis, L. Su, and P. Coplan. 2004. A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults. Vaccine 22(5-6):766-772.

Block, S. L., D. R. Brown, A. Chatterjee, M. A. Gold, H. L. Sings, A. Meibohm, A. Dana, R. M. Haupt, E. Barr, G. M. Tamms, H. Zhou, and K. S. Reisinger. 2010. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatric Infectious Disease Journal 29(2):95-101.

Braun, M. M., P. A. Patriarca, and S. S. Ellenberg. 1997. Syncope after immunization. Archives of Pediatrics and Adolescent Medicine 151(3):255-259.

Buttery, J. P., S. Madin, N. W. Crawford, S. Elia, S. La Vincente, S. Hanieh, L. Smith, and B. Bolam. 2008. Mass psychogenic response to human papillomavirus vaccination. Medical Journal of Australia 189(5):261-262.

D’Heilly, S. J., M. A. Blade, and K. L. Nichol. 2006. Safety of influenza vaccinations administered in nontraditional settings. Vaccine 24(18):4024-4027.

Dobardzic, A., H. Izurieta, E. J. Woo, J. Iskander, S. Shadomy, C. Rupprecht, R. Ball, and M. M. Braun. 2007. Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine 25(21):4244-4251.

Dobson, S., D. Scheifele, and A. Bell. 1995. Assessment of a universal, school-based hepatitis B vaccination program. Journal of the American Medical Association 274(15):1209-1213.

D’Souza, R. M., S. Campbell-Lloyd, D. Isaacs, M. Gold, M. Burgess, F. Turnbull, and E. O’Brien. 2000. Adverse events following immunisation associated with the 1998 Australian measles control campaign. Communicable Diseases Intelligence 24(2):27-33.

DuVernoy, T. S., and M. M. Braun. 2000. Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998. Pediatrics 106(4):E52.

FDA (Food and Drug Administration). 2010. Descriptive summary of VAERS reports indicating serious adverse events following influenza vaccination discussed in Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring. Vellozzi et al., Vaccine, 2009. 27:2114-2120: Sent to the Committee to Review Adverse Effects of Vaccines by the Food and Drug Administration.

Genc, H., A. Karagoz, M. Saracoglu, E. Sert, and H. R. Erdem. 2005. Complex regional pain syndrome type-I after rubella vaccine. European Journal of Pain 9(5):517-520.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement